Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$56.45

-0.1 (-0.18%)

07:26
07/10/18
07/10
07:26
07/10/18
07:26

FDA PDUFA Date for Bristol-Myers Opdivo-Yervoy combination is July 10, 2018

  • 10

    Jul

BMY Bristol-Myers
$56.45

-0.1 (-0.18%)

05/24/18
MZHO
05/24/18
NO CHANGE
Target $103
MZHO
Buy
Nektar is Bristol-Myers' best chance in immuno-oncology, says Mizuho
Nektar Therapeutics' (NKTR) NKTR-214 asset is the best shot Bristol-Myers Squibb (BMY) has to retain its footing in the competitive immuno-oncology space, Mizuho analyst Difei Yang tells investors in a research note. The analyst says that recent data in non-small cell lung cancer presented by Merck (MRK) on Keytruda saw the company jump ahead of Bristol's Opdivo in this key indication. Upcoming data of the Opdivo/NKTR-214 combo at ASCO on June 2 will be key on 100 patients across multiple indications, Yang contends. She believes Bristol stands at risk of losing significant market share in the growing immuno-oncology space. Ahead of the data, the analyst reiterates a Buy rating on Nektar with a $103 price target.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/19/18
06/19/18
DOWNGRADE
Target $300

In Line
Madrigal cut to In Line at Evercore ISI following run-up in price, expectations
As previously reported, Evercore ISI analyst Josh Schimmer downgraded Madrigal Pharmaceuticals (MDGL) to In Line from Outperform, stating that he has no real incremental reason to raise his $300 price target, which the stock has achieved following the company's encouraging Phase 2 results for MGL-3196 and a Bloomberg report that has driven takeover speculation. Given current investor sentiment, anything short of either an acquisition or a "massive" collaboration like Bristol-Myers' (BMY) with Nektar (NKTR) will fall short of expectations, Schimmer tells investors.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

ZS

Zscaler

$36.79

-1.16 (-3.06%)

16:14
10/18/18
10/18
16:14
10/18/18
16:14
Initiation
Zscaler initiated  »

Zscaler initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BNFT

Benefitfocus

$31.94

-1.41 (-4.23%)

16:14
10/18/18
10/18
16:14
10/18/18
16:14
Initiation
Benefitfocus initiated  »

Benefitfocus initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

INDB

Independent Bank

$81.30

1.1 (1.37%)

16:13
10/18/18
10/18
16:13
10/18/18
16:13
Earnings
Independent Bank reports Q3 adjusted EPS $1.27, consensus $1.20 »

Total assets of $8.4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 24

    Oct

HALO

Halozyme

$17.60

-0.34 (-1.90%)

16:13
10/18/18
10/18
16:13
10/18/18
16:13
Initiation
Halozyme initiated  »

Halozyme assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

ETFC

E-Trade

$48.87

-1.7 (-3.36%)

16:12
10/18/18
10/18
16:12
10/18/18
16:12
Hot Stocks
E-Trade initiates 14c per share quarterly dividend »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SREV

ServiceSource

$2.61

-0.07 (-2.61%)

16:12
10/18/18
10/18
16:12
10/18/18
16:12
Hot Stocks
ServiceSource names Richard G. Walker CFO »

ServiceSource announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETFC

E-Trade

$48.92

-1.65 (-3.26%)

16:12
10/18/18
10/18
16:12
10/18/18
16:12
Hot Stocks
Breaking Hot Stocks news story on E-Trade »

E-Trade announces $1B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

WERN

Werner

$32.40

-0.97 (-2.91%)

16:11
10/18/18
10/18
16:11
10/18/18
16:11
Earnings
Werner reports Q3 EPS 66c, consensus 60c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

RGLS

Regulus

$1.98

-0.04 (-1.98%)

16:11
10/18/18
10/18
16:11
10/18/18
16:11
Hot Stocks
Regulus regains compliance with NASDAQ listing requirements »

Regulus received notice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETFC

E-Trade

$48.92

-1.65 (-3.26%)

16:11
10/18/18
10/18
16:11
10/18/18
16:11
Earnings
E-Trade reports Q3 EPS 88c excluding 12c benefit, consensus 82c »

Diluted earnings per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SREV

ServiceSource

$2.61

-0.07 (-2.61%)

16:11
10/18/18
10/18
16:11
10/18/18
16:11
Earnings
ServiceSource cuts FY18 revenue view to $238M-$240M from $246M-$249M »

Consensus $247.91M. Based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$17.00

-0.76 (-4.28%)

16:11
10/18/18
10/18
16:11
10/18/18
16:11
Initiation
NuCana initiated  »

NuCana initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SREV

ServiceSource

$2.61

-0.07 (-2.61%)

16:11
10/18/18
10/18
16:11
10/18/18
16:11
Earnings
ServiceSource reports preliminary Q3 revenue $57M, consensus $60.52M »

The company now expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMNB

American National Bankshares

$37.19

-0.22 (-0.59%)

16:10
10/18/18
10/18
16:10
10/18/18
16:10
Earnings
American National Bankshares reports Q3 EPS 66c, consensus 67c »

Book value per common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$30.02

-1.36 (-4.33%)

16:10
10/18/18
10/18
16:10
10/18/18
16:10
Initiation
Clovis initiated  »

Clovis assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

EGP

EastGroup Properties

$93.65

0.15 (0.16%)

16:10
10/18/18
10/18
16:10
10/18/18
16:10
Earnings
Breaking Earnings news story on EastGroup Properties »

EastGroup Properties sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 07

    Nov

SKX

Skechers

$26.10

-0.59 (-2.21%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
Skechers sees Q4 EPS 20c-25c, consensus 18c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

EGP

EastGroup Properties

$93.63

0.13 (0.14%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
EastGroup Properties reports Q3 FFO $1.17, consensus $1.14 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 07

    Nov

EXPO

Exponent

$47.38

-1.12 (-2.31%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
Exponent sees FY18 revenue growth in high-single digits »

Exponent CFO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TEAM

Atlassian

$82.36

-1.27 (-1.52%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
Atlassian sees FY19 EPS 78c, consensus 77c »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SKX

Skechers

$26.13

-0.56 (-2.10%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
Skechers reports Q3 EPS 58c, consensus 51c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CRBP

Corbus Pharmaceuticals

$7.83

0.29 (3.85%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Hot Stocks
Corbus Pharmaceuticals presents new data on lenabasum at NACFC »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTT

CatchMark Timber

$9.63

-0.21 (-2.13%)

16:08
10/18/18
10/18
16:08
10/18/18
16:08
Hot Stocks
CatchMark Timber reports 'negligible damage' from recent Hurricanes »

CatchMark Timber Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

AKTS

Akoustis

$5.02

-0.735 (-12.78%)

16:08
10/18/18
10/18
16:08
10/18/18
16:08
Syndicate
Akoustis Spot Secondary price range $4.00-$4.25 »

Oppenheimer is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

TEAM

Atlassian

$82.18

-1.45 (-1.73%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Earnings
Atlassian sees Q2 EPS 21c, consensus 20c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.